27
Participants
Start Date
July 31, 2007
Primary Completion Date
September 30, 2008
Study Completion Date
June 30, 2009
KP-1461
Oral dosage, 1600 mg bid for 124 days
AIDS Community Research Initiative of America, New York
Mount Sinai Medical Center, New York
Albany Medical College, Albany
Thomas Jefferson University, Division of Infectious Disease, Philadelphia
Dupont Circle Physician's Group, Washington D.C.
Whitman-Walker Clinic, Washington D.C.
Institute of Human Virology, University of Maryland, Baltimore
CARE-ID, Annandale
Duke University Medical Center, Durham
AIDS Research Consortium of Atlanta, Atlanta
Orlando Immunology Center, Orlando
Treasure Coast Infectious Disease Consultants, Vero Beach
Wohlfeiler, Piperato and Associates, LLC, North Miami Beach
Comprehensive Care Center -- HIV Clinical Research, Fort Lauderdale
University of Cincinnati Medical Center, Cincinnati
Northstar Medical Center, Chicago
Dybedal Center for Clinical Research, Kansas City University of Medicine and Biosciences, Kansas City
University of Kansas School of Medicine - PriVia, The Research Centers of Via Christi, Wichita
Health for Life Clinic, Little Rock
Charlton Methodist Hospital, Dallas
University of Texas Health Science Center, Houston
Southwest CARE Center, Santa Fe
Light Source Medical/U. of Southern California, Los Angeles
Living Hope Clinical Foundation, Long Beach
UCSD Antiviral Research Center, San Diego
Quest Clinical Research, San Francisco
ACTU at CARES/UC Davis, Sacramento
University of Washington AIDS Clinical Trials Unit, Seattle
Community Research Initiative of New England, Boston
St. Michael's Medical Center, Newark
Clinical Research Puerto Rico, Inc., San Juan
Lead Sponsor
Koronis Pharmaceuticals.
INDUSTRY